Sugi Predict

Sugi Predict / Compounds / SCHEMBL11070977

SCHEMBL11070977

SCHEMBL11070977

CC(C)(O)c1cc(Cl)nc(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 9/20 0.37
▸ CYP11B1 P15538 8/20 0.37
▸ S1PR2 O95136 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NR4A2 P43354 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ TNKS O95271 2/20 0.33
▸ PARP1 P09874 2/20 0.33
▸ TNKS2 Q9H2K2 2/20 0.33
▸ PDE2A O00408 2/20 0.33
▸ PDE10A Q9Y233 2/20 0.33
▸ CCR9 P51686 1/20 0.33
▸ HSD11B1 P28845 1/20 0.32
▸ HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14707739 0.87 HTT (0.38) CYP11B2CYP11B1MEN1KMT2ANR4A2
SCHEMBL30946587 0.82 PDE2A (0.38) CYP11B2CYP11B1PDE2APDE10A
SCHEMBL11068771 0.82 SMN1; SMN2 (0.36) CYP11B2CYP11B1
SCHEMBL6122122 0.82 PDE2A (0.38) CYP11B2CYP11B1PDE2APDE10A
SCHEMBL2608422 0.79 GABRA1 (0.42) S1PR2PDE10ACCR9HTT
SCHEMBL31047260 0.78 HSD11B1 (0.40) CYP11B2CYP11B1HSD11B1
SCHEMBL30211257 0.75 S1PR2 (0.43) CYP11B2CYP11B1S1PR2NR4A2KCNH2
SCHEMBL25379591 0.75 GABRA2 (0.33) S1PR2HTT
SCHEMBL29197134 0.75 S1PR2 (0.32) S1PR2MEN1KMT2A
SCHEMBL31047289 0.75 GABRA2 (0.33) S1PR2HSD11B1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024193689-A1 PYRIDINOPYRROLE DERIVATIVE AND USE THEREOF IN DRUGS 广东东阳光药业股份有限公司 2024-09-26 — — WO disclosed
CN-118684665-A Pyridopyrrole derivatives and their use in medicine 广东东阳光药业股份有限公司 2024-09-24 — — CN disclosed
US-11021444-B2 Antiviral compounds Janssen Biopharma, Inc. (US) 2021-06-01 — — US disclosed
US-20190263754-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2019-08-29 — — US disclosed
US-20180065932-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2018-03-08 — — US disclosed
US-20180065932-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2018-03-08 — — US disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 — — US disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 — — US disclosed
WO-2015026792-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2015-02-26 — — WO disclosed
US-4474602-A Substituted pyridyl compounds, herbicidal compositions and method of use THE DOW CHEMICAL COMPANY (US) 1984-10-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263754-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 CYP11B2 3994/4885CYP11B1 4124/4885S1PR2 1781/4885
US-11021444-B2 Antiviral compounds MAVS, SARS1, ZC3HAV1 CYP11B2 3994/4885CYP11B1 4124/4885S1PR2 1781/4885
US-20180065932-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 CYP11B2 3994/4885CYP11B1 4124/4885S1PR2 1781/4885
US-20150065504-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 CYP11B2 3994/4885CYP11B1 4124/4885S1PR2 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.